Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HRP004
MIFTS: 63

Herpes Zoster

Categories: Infectious diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Herpes Zoster

About this section

MalaCards integrated aliases for Herpes Zoster:

Name: Herpes Zoster 12 77 26 55 56 3 45 15 17
Shingles 12 77 26 55 44 3 15 64
Zoster 26 3
Herpes Zoster Disease 74
Herpes Zona 12

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:8536
ICD9CM 36 053
MeSH 45 D006562
NCIt 51 C71079
SNOMED-CT 69 4740000
UMLS 74 C0019360
Sources

Summaries for Herpes Zoster

About this section
MedlinePlus : 44 What is shingles? Shingles is an outbreak of rash or blisters on the skin. It is caused by the varicella-zoster virus - the same virus that causes chickenpox. After you have chickenpox, the virus stays in your body. It may not cause problems for many years. But as you get older, the virus may reappear as shingles. Is shingles contagious? Shingles is not contagious. But you can catch chickenpox from someone with shingles. If you've never had chickenpox or the chickenpox vaccine, try to stay away from anyone who has shingles. If you have shingles, try to stay away from anyone who has not had chickenpox or the chickenpox vaccine, or anyone who might have a weak immune system. Who is at risk for shingles? Anyone who has had chickenpox is at risk for getting shingles. But this risk goes up as you get older; shingles is most common in people over age 50. People with weakened immune systems are at higher risk of getting shingles. This includes those who Have immune system diseases such as HIV/AIDS Have certain cancers Take immunosuppressive drugs after an organ transplant Your immune system may be weaker when you have an infection or are stressed. This can raise your risk of shingles. It is rare, but possible, to get shingles more than once. What are the symptoms of shingles? Early signs of shingles include burning or shooting pain and tingling or itching. It is usually on one side of the body or face. The pain can be mild to severe. One to 14 days later, you will get a rash. It consists of blisters that typically scab over in 7 to 10 days. The rash is usually a single stripe around either the left or the right side of the body. In other cases, the rash occurs on one side of the face. In rare cases (usually among people with weakened immune systems), the rash may be more widespread and look similar to a chickenpox rash. Some people may also have other symptoms: Fever Headache Chills Upset stomach What are the complications of shingles? Shingles can cause complications: Postherpetic neuralgia (PHN) is most common complication of shingles. It causes severe pain in the areas where you had the shingles rash. It usually gets better in a few weeks or months. But some people can have pain from PHN for many years, and it can interfere with daily life. Vision loss can happen if shingles affects your eye. It may be temporary or permanent. Hearing or balance problems are possible if you have shingles within or near your ear. You may also have weakness of the muscles on that side of your face. These problems can be temporary or permanent. Very rarely, shingles can also lead to pneumonia, brain inflammation (encephalitis), or death. How is shingles diagnosed? Usually your health care provider can diagnose shingles by taking your medical history and looking at your rash. In some cases, your provider may scrap off tissue from the rash or swab some fluid from the blisters and send the sample to a lab for testing. What are the treatments for shingles? There is no cure for shingles. Antiviral medicines may help to make the attack shorter and less severe. They may also help prevent PHN. The medicines are most effective if you can take them within 3 days after the rash appears. So if you think you might have shingles, contact your health care provider as soon as possible. Pain relievers may also help with the pain. A cool washcloth, calamine lotion, and oatmeal baths may help relieve some of the itching. Can shingles be prevented? There are vaccines to prevent shingles or lessen its effects. The Centers for Disease Control and Prevention recommends that healthy adults 50 years and older get the Shingrix vaccine. You need two doses of the vaccine, given 2 to 6 months apart. Another vaccine, Zostavax, may be used in certain cases.

MalaCards based summary : Herpes Zoster, also known as shingles, is related to postherpetic neuralgia and human immunodeficiency virus infectious disease, and has symptoms including fever, paresthesia and headache. An important gene associated with Herpes Zoster is DPYD (Dihydropyrimidine Dehydrogenase), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Acyclovir and Foscarnet have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and t cells.

Disease Ontology : 12 A viral infectious disease that results in infection located in nerve fiber, has material basis in Human herpesvirus 3, which reactivates after appearing as chickenpox in childhood. The virus is transmitted by direct contact with the rash, which can develop into chickenpox in newly-infected individuals. The infection has symptom rash which is followed by blisters, has symptom headache, has symptom fever, has symptom malaise, has symptom itching, has symptom burning pain, and has symptom paresthesia.

Genetics Home Reference : 26 Shingles (also known as herpes zoster) results from infection by the varicella zoster virus. This common virus causes chickenpox (also known as varicella), which is characterized by itchy spots on the skin that cover the whole body and usually occurs in childhood or adolescence. After the body fights the initial infection, the varicella zoster virus remains in nerve cells for the rest of a person's life. Because the virus is controlled by immune system cells called T cells, it is generally inactive (latent) and typically causes no health problems. However, in some people, the virus becomes active again (reactivates) and causes shingles. Shingles can occur at any age, although it is rare in childhood and becomes more common after age 50.

CDC : 3 Almost 1 out of every 3 people in the United States will develop shingles, also known as zoster or herpes zoster, in their lifetime. There are an estimated 1 million cases of shingles each year in this country. Anyone who has recovered from chickenpox may develop shingles; even children can get shingles. However, the risk of shingles increases as you get older.

NINDS : 55 Shingles (herpes zoster) is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chickenpox — the varicella-zoster virus. The first sign of shingles is often burning or tingling pain (which can be severe), or sometimes numbness or itch,generally on one side of the body. After several days or a week, a rash of fluid-filled blisters, similar to chickenpox, appears in one area on one side of the body. Shingles pain can be mild or intense.  Some people have mostly itching; some feel pain from the gentlest touch or breeze.  The most common location for shingles is a band, called a dermatome, spanning one side of the trunk around the waistline. Anyone who has had chickenpox is at risk for shingles.  Scientists think that some of the virus particles from the original exposure to the varicella-zoster virus,leave the skin blisters and move into the nervous system.  When the varicella-zoster virus reactivates, the virus moves back down the long nerve fibers that extend from the sensory cell bodies to the skin.  The viruses multiply, the tell-tale rash erupts, and the person now has shingles.

PubMed Health : 64 About shingles: Anyone who has already had chickenpox is at risk of developing shingles later on. Both are caused by the same virus, the varicella-zoster virus. This virus stays dormant (inactive) in the body after a chickenpox infection. But it can become active again years later and cause shingles (herpes zoster): a rash with blisters that usually forms a band across the skin and is often very painful. The rash normally only affects one side of the body.People who have been vaccinated against chickenpox can still get shingles. But this is thought to be less common than developing it after having chickenpox.Shingles is particularly common in older people. Although it can be very unpleasant, it’s usually over in about two to four weeks if there are no complications.Shingles is contagious, but only for people who have never had chickenpox. In that case the infection only causes chickenpox, and not shingles.

Wikipedia : 77 Shingles, also known as zoster or herpes zoster, is a viral disease characterized by a painful skin rash... more...

Sources

Related Diseases for Herpes Zoster

About this section

Diseases related to Herpes Zoster via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 652)
# Related Disease Score Top Affiliating Genes
1 postherpetic neuralgia 33.3 HLA-A HLA-B
2 human immunodeficiency virus infectious disease 30.8 IFNG IL10 IL2
3 anterior uveitis 30.6 HLA-A HLA-B
4 uveitis 30.5 HLA-B IFNA2 IFNG IL10
5 variola major 30.5 IFNG IL2
6 pityriasis rosea 30.4 HLA-A HLA-B
7 discoid lupus erythematosus 30.4 IFNA2 IL10
8 colitis 30.4 IFNG IL10 IL2
9 rubella 30.4 HLA-A HLA-B IL10
10 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 30.3 IFNG IL10 IL2
11 ulcerative colitis 30.3 IFNG IL10 IL2
12 folliculitis 30.3 FCGR3A IFNG
13 autoimmune disease 30.0 COL17A1 IFNG IL10 IL2
14 chronic graft versus host disease 30.0 IFNG IL10
15 acquired immunodeficiency syndrome 30.0 HCP5 HLA-B IFNA2 IFNG IL10 IL2
16 neutropenia 30.0 DPYD FCGR3A IFNA2
17 rheumatic disease 29.9 HLA-B IFNG IL10
18 panuveitis 29.9 HLA-A HLA-B IL10
19 lepromatous leprosy 29.9 IFNG IL10 IL2
20 vogt-koyanagi-harada disease 29.9 HLA-A HLA-B IL10
21 toxic shock syndrome 29.9 IFNG IL10 IL2
22 histoplasmosis 29.9 HLA-A HLA-B IFNG
23 tetanus 29.9 IFNG IL10 IL2
24 pulmonary tuberculosis 29.9 IFNG IL10 IL2
25 severe cutaneous adverse reaction 29.8 HCP5 HLA-A HLA-B
26 mouth disease 29.8 IFNG IL10 TRPV1
27 graft-versus-host disease 29.8 HLA-A HLA-B IFNG IL10 IL2
28 leprosy 3 29.8 IFNG IL10 IL2
29 common variable immunodeficiency 29.8 IFNG IL10 IL2
30 connective tissue disease 29.7 IFNG IL10 TRPV1
31 hematopoietic stem cell transplantation 29.7 HLA-A HLA-B IFNG IL10 IL2
32 fixed drug eruption 29.7 IFNG IL2
33 poliomyelitis 29.6 FCGR3A IFNG IL10
34 cytomegalovirus retinitis 29.5 HLA-A HLA-B IFNG
35 aplastic anemia 29.5 HLA-A HLA-B IFNG IL2
36 aphthous stomatitis 29.5 HLA-A HLA-B IL10 IL2
37 dermatitis, atopic 29.5 IFNG IL10 IL2
38 burning mouth syndrome 29.4 IL2 TRPV1
39 human immunodeficiency virus type 1 29.1 HLA-A HLA-B IFNG IL10 IL2 TKT
40 malaria 28.6 GYPC HLA-A HLA-B IFNG IL10 IL2
41 geniculate herpes zoster 13.0
42 herpes zoster ophthalmicus 12.8
43 myoclonus and ataxia 12.3
44 congenital varicella syndrome 12.0
45 immunodeficiency 50 11.2
46 salivary gland disease 11.0
47 cytomegalic inclusion disease 11.0
48 aids - neurological complications 11.0
49 neurological consequences of cytomegalovirus infection 11.0
50 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 11.0

Graphical network of the top 20 diseases related to Herpes Zoster:



Diseases related to Herpes Zoster
Sources

Symptoms & Phenotypes for Herpes Zoster

About this section

Symptoms:

12
  • • fever
  • • paresthesia
  • • headache
  • • malaise
  • • itching
  • • rash which is followed by blisters
  • • burning pain

UMLS symptoms related to Herpes Zoster:


seizures, tremor, fever, angina pectoris, pruritus, back pain, pain, headache, syncope, chronic pain, sciatica, exanthema, vertigo/dizziness, equilibration disorder, sleeplessness
Sources

Drugs & Therapeutics for Herpes Zoster

About this section

PubMedHealth treatment related to Herpes Zoster: 64

Pain and fever can be relieved with medication such as acetaminophen (paracetamol) or acetylsalicylic acid (the drug in medicines like Aspirin). Prescription painkillers are sometimes used to relieve more severe pain.Thorough skin care is recommended if you have shingles. Antiseptic or anti-itch lotions, gels and powders are often used to relieve the itching and dry out the blisters. Most of them contain tanins, zinc, menthol or polidocanol. If blisters have already formed, people are sometimes advised to use cooling wraps. But there’s no good scientific research on how well these treatments work.Drugs that fight viruses can be used in people who are over 50 or have a weakened immune system, if the condition is very severe, affects the head and neck area, or there is a higher risk of complications. This is known as "antiviral therapy." Using antiviral medication early on can help speed up recovery and make the pain go away faster. So people are advised to start antiviral therapy no later than 72 hours after the rash starts. In severe cases the medicine can also be given through a drip into a vein (intravenous infusion). If the ear is affected, steroids are often used too. But it still isn’t clear what pros and cons this kind of combination therapy may have.

Drugs for Herpes Zoster (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 452)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acyclovir Approved Phase 4,Phase 3,Phase 2,Phase 1 59277-89-3 2022
2
Foscarnet Approved Phase 4 4428-95-9, 63585-09-1 3415
3
Ethanol Approved Phase 4 64-17-5 702
4
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 302-25-0
5
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-24-8 5755
6
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable 2921-57-5
7
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
8
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
9
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 83-43-2 6741
10
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
11
Capsaicin Approved Phase 4,Phase 3,Phase 2 404-86-4 1548943
12
Natalizumab Approved, Investigational Phase 4 189261-10-7
13
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
14
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60142-96-3 3446
15
Budesonide Approved Phase 4,Phase 2 51333-22-3 5281004 63006
16
leucovorin Approved Phase 4,Phase 3,Phase 2 58-05-9 143 6006
17
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
18
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
19
Tofacitinib Approved, Investigational Phase 4,Phase 2 477600-75-2
20
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 148553-50-8 5486971
21
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541
22
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
23
Infliximab Approved Phase 4,Phase 3 170277-31-3
24
Bupivacaine Approved, Investigational Phase 4,Phase 2 38396-39-3, 2180-92-9 2474
25 Vedolizumab Approved Phase 4 943609-66-3
26
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
27
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
28
Azathioprine Approved Phase 4 446-86-6 2265
29
Certolizumab pegol Approved Phase 4 428863-50-7
30
Mercaptopurine Approved Phase 4 50-44-2 667490
31
St. John's Wort Approved, Investigational, Nutraceutical Phase 4 84082-80-4
32
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Not Applicable 1406-16-2
35
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1 50-14-6 5280793
36
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
37
Phosphonoacetic Acid Experimental Phase 4 4408-78-0 546
38
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Not Applicable 2920-86-7
39 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
43 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2
44 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 566)
# Name Status NCT ID Phase Drugs
1 The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination Unknown status NCT01830283 Phase 4
2 Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster Unknown status NCT02151240 Phase 4 Foscarnet Sodium;Acyclovir
3 The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination Unknown status NCT01866566 Phase 4
4 Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine Unknown status NCT02146469 Phase 4
5 Pilot Study to Describe Immune Responses of Healthy Women Following Immunization With Varicella Zoster Virus Vaccine Unknown status NCT02514018 Phase 4
6 Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children Unknown status NCT01982409 Phase 4
7 Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation Unknown status NCT00940940 Phase 4
8 Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies Unknown status NCT00865540 Phase 4 prednisolone acetate 1%;ketorolac tromethamine 0.4%;nepafenac 0.1%;methylcellulose 0.5%
9 Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox Unknown status NCT02383797 Phase 4
10 "Equistasi" and Gait in Hemiparesis Unknown status NCT02714478 Phase 4
11 Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain Unknown status NCT01264237 Phase 4 Etoricoxib;Placebo
12 Qutenza for Critical Ischaemia in End Stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
13 Olive Oil's Cream Effectiveness in Prevention of Pressure Ulcers in Immobilized Patients in Primary Care Unknown status NCT01595347 Phase 4 Hyper-oxigenated fatty acid
14 T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020 Completed NCT01911065 Phase 4
15 Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine Completed NCT02173899 Phase 4
16 Safety of a Second Dose of Biken's Varicella Vaccine Completed NCT00830648 Phase 4
17 A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster Completed NCT02152800 Phase 4 valacyclovir hydrocholoride
18 ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034) Completed NCT01556451 Phase 4
19 Acupuncture in Herpes Zoster Neuralgia (ACUZoster) Completed NCT00885586 Phase 4 gabapentine
20 Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin Completed NCT01684072 Phase 4
21 Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine Completed NCT01817270 Phase 4
22 Zostavax® at Minimum Release Specification Approaching Expiry (V211-044) Completed NCT00681031 Phase 4
23 Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™ Completed NCT02958345 Phase 4
24 Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine Completed NCT01815073 Phase 4
25 Varicella Vaccination With Pulmicort Completed NCT00641446 Phase 4 budesonide;varicella zoster virus
26 The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children Completed NCT01138215 Phase 4
27 ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020) Completed NCT00550745 Phase 4
28 Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis Completed NCT01356004 Phase 4 live attenuated chicken pox vaccine;saline, efficacy
29 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
30 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
31 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
32 Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza Completed NCT01693380 Phase 4
33 Palatability Testing of a New Paediatric Formulation of Valacyclovir Completed NCT01682109 Phase 4 Valacyclovir
34 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
35 MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine Completed NCT02225327 Phase 4
36 An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate Completed NCT02187055 Phase 4 Tofacitinib with methotrexate;Tofacitinib without methotrexate
37 Pregabalin in the Treatment of Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
38 Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
39 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
40 Natalizumab Temporary Discontinuation Study Completed NCT02775110 Phase 4
41 A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation Completed NCT00048165 Phase 4 Daclizumab;Methylprednisolone;Mycophenolate mofetil;Placebo;cyclosporine
42 Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD) Completed NCT00760747 Phase 4 Atomoxetine
43 The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis Completed NCT01581359 Phase 4 Triptorelin acetate
44 Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients Recruiting NCT03016884 Phase 4
45 Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation Recruiting NCT03493776 Phase 4
46 Immune Response to Shingles Vaccination Recruiting NCT02624375 Phase 4 Zoster Vaccine Live
47 Zoster Eye Disease Study Recruiting NCT03134196 Phase 4 Masked Placebo;Masked Oral Valacyclovir
48 Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine Recruiting NCT03330171 Phase 4
49 Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Recruiting NCT03798691 Phase 4
50 Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia Recruiting NCT03809702 Phase 4 Pregabalin;Placebo

Search NIH Clinical Center for Herpes Zoster

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: herpes zoster

Sources

Genetic Tests for Herpes Zoster

About this section
Sources

Anatomical Context for Herpes Zoster

About this section

MalaCards organs/tissues related to Herpes Zoster:

42
Skin, Eye, T Cells, Bone, Brain, Testes, Kidney

The Foundational Model of Anatomy Ontology organs/tissues related to Herpes Zoster:

20
Nerve Fiber
Sources

Publications for Herpes Zoster

About this section

Articles related to Herpes Zoster:

(show top 50) (show all 3637)
# Title Authors Year
1
A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. ( 30885757 )
2019
2
Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis. ( 30630365 )
2019
3
A case of herpes zoster infection mimicking carpal tunnel syndrome. ( 30860133 )
2019
4
High rate of recurrence of herpes zoster-related ocular disease after phacoemulsification cataract surgery. ( 30954337 )
2019
5
Herpes Zoster Ophthalmicus, Central Retinal Artery Occlusion, and Neovascular Glaucoma in an Immunocompetent Individual. ( 30820294 )
2019
6
Abdominal Wall Pseudohernia and Colonic Pseudo-obstruction as Complications of Herpes Zoster. ( 29723690 )
2019
7
Real-world database investigating the association between diabetes mellitus and herpes zoster in Taiwan. ( 31045823 )
2019
8
Necrotizing Fasciitis Following Herpes Zoster Ophthalmicus in an Immunocompromised Patient. ( 30805235 )
2019
9
Case of herpes zoster with herpetic folliculitis complicated with meningitis: Immunohistochemistry. ( 30888068 )
2019
10
Herpes zoster of the external ear. ( 30604491 )
2019
11
Using Number Needed to Harm to Put the Risk of Herpes Zoster From Tofacitinib in Perspective. ( 30605536 )
2019
12
Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults. ( 30608953 )
2019
13
Evaluation of VZV-specific Cell-mediated Immunity by Interferon-gamma ELISA in Adults ≥50 Years of Age Administered a Herpes Zoster Vaccine. ( 30613990 )
2019
14
Trends in U.S. Community hospitalizations due to herpes zoster: 2001-2015. ( 30616954 )
2019
15
Severe Herpes Zoster Following Varicella Vaccination in Immunocompetent Young Children. ( 30628536 )
2019
16
Herpes zoster infection. ( 30630827 )
2019
17
Recurrence Rate of Herpes Zoster and Its Risk Factors: a Population-based Cohort Study. ( 30636941 )
2019
18
Models for optimally controlling varicella and herpes zoster by varicella vaccination: a comparative study. ( 30652233 )
2019
19
Economic Analysis of Herpes Zoster in a Hospital Setting in Hong Kong. ( 30653238 )
2019
20
Incidence and Risk Factors for Developing Herpes Zoster Among a Cohort of Patients Diagnosed With Lymphoma at a Community Cancer Center. ( 30655095 )
2019
21
Herpes zoster ophthalmicus. ( 30655269 )
2019
22
Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain. ( 30660981 )
2019
23
Disseminated herpes zoster following treatment with benralizumab. ( 30666793 )
2019
24
Development of herpes zoster during infliximab treatment for pediatric generalized pustular psoriasis: A case report. ( 30672104 )
2019
25
Update in Herpes Zoster Prevention and the Role of Dermatologists ( 30681788 )
2019
26
Costs of herpes zoster complications in older adults: A cohort study of US claims database. ( 30685248 )
2019
27
Herpes zoster incidence in Germany - an indirect validation study for self-reported disease data from pretest studies of the population-based German National Cohort. ( 30700258 )
2019
28
Pseudohernia preceding disseminated herpes zoster. ( 30712837 )
2019
29
The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting. ( 30727971 )
2019
30
Long-term outcomes of penetrating keratoplasty for corneal complications of herpes zoster ophthalmicus. ( 30733209 )
2019
31
Ultrasound-Guided Cervical Nerve Root Block for the Treatment of Acute Cervical Herpes Zoster: A Randomized Controlled Clinical Study. ( 30734476 )
2019
32
Comedones appearing after herpes zoster infection: Koebner phenomenon or Wolf's isotopic response? ( 30734718 )
2019
33
Calabria: a successful experience implementing Herpes Zoster vaccination strategies. ( 30737649 )
2019
34
Herpes Zoster in Pregnancy. ( 30740856 )
2019
35
Mortality risk after herpes zoster infection in end-stage renal disease patients. ( 30746135 )
2019
36
Incidence and risk factors for herpes zoster after adult liver transplantation. ( 30746357 )
2019
37
Association between statin use and herpes zoster: systematic review and meta-analysis. ( 30765397 )
2019
38
A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. ( 30776797 )
2019
39
Review: Adjuvant recombinant subunit vaccine prevents herpes zoster more than live attenuated vaccine in adults ≥ 50 years. ( 30776803 )
2019
40
Impact of a multi-component immunization intervention on pneumococcal and herpes zoster vaccinations: A randomized controlled trial of community pharmacies in 2 states. ( 30777645 )
2019
41
Axillary mononeuropathy after herpes zoster infection misdiagnosed as neuropathic pain. ( 30785247 )
2019
42
The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy. ( 30793003 )
2019
43
Altered gray matter volume in patients with herpes zoster and postherpetic neuralgia. ( 30799946 )
2019
44
Adult vaccination as the cornerstone of successful ageing: the case of herpes zoster vaccination. A European Interdisciplinary Council on Ageing (EICA) expert focus group. ( 30805865 )
2019
45
AF1q gene polymorphism proteomic markers in herpes zoster-infected leukemia patients. ( 30821139 )
2019
46
Vaccine Prevention of Herpes Zoster in Organ Transplant Recipients: A Busy Intersection of Immune Responses to Foreign Antigens. ( 30843045 )
2019
47
Herpes Zoster Ophthalmicus Review and Prevention. ( 30844951 )
2019
48
Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine : Statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute. ( 30848293 )
2019
49
Herpes zoster ophthalmicus pseudodendrites: for topical antivirals or not? ( 30850997 )
2019
50
Herpes zoster onset 9 years after first varicella zoster vaccination in a 11 year old child - a case report. ( 30887925 )
2019
Sources

Variations for Herpes Zoster

About this section
Sources

Expression for Herpes Zoster

About this section
Search GEO for disease gene expression data for Herpes Zoster.
Sources

Pathways for Herpes Zoster

About this section

Pathways related to Herpes Zoster according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 67
Show member pathways
 13.17 HLA-A HLA-B IFNA2 IFNG IL10 IL2
2
Allograft rejection 38 1
Show member pathways
 12.62 HLA-A HLA-B IFNA2 IFNG IL10 IL2
3
Interferon gamma signaling 67
Show member pathways
 12.36 HLA-A HLA-B IFNA2 IFNG
4
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.22 IFNA2 IFNG IL10 IL2
5
Tuberculosis 38
12.06 FCGR3A IFNA2 IFNG IL10
6
Phagosome 38
11.96 FCGR3A HLA-A HLA-B
7
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 67
11.9 FCGR3A HLA-A HLA-B
8
Th1 Differentiation Pathway 66
Show member pathways
 11.88 IFNG IL10 IL2
9
IL12-mediated signaling events 1
Show member pathways
 11.81 HLA-A IFNG IL2
10
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.73 IFNA2 IFNG IL10 IL2
11
Jak-Stat Signaling Pathway (sino) 68
11.7 IFNA2 IFNG IL10 IL2
12
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 11.64 HLA-A HLA-B IFNA2 IFNG IL10 IL2
13
Innate Lymphoid Cell Differentiation Pathways 66
11.63 IFNG IL10 IL2
14
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 11.58 FCGR3A HLA-A HLA-B IFNA2 IFNG IL2
15
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.5 HLA-A IFNG IL2
16
Dendritic Cells Developmental Lineage Pathway 66
11.43 IFNA2 IFNG IL10 IL2
17
Malaria 38
11.39 GYPC IFNG IL10
18
Th2 Differentiation Pathway 66
11.33 IFNG IL10 IL2
19
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.31 FCGR3A IFNG IL10 IL2
20
Type II interferon signaling (IFNG) 1
11.22 HLA-B IFNA2 IFNG
21
Cytokines and Inflammatory Response 1
11.07 IFNG IL10 IL2
22
IL12 signaling mediated by STAT4 1
11.06 IFNG IL2
23
Antigen Presentation- Folding, assembly and peptide loading of class I MHC 67
11.01 HLA-A HLA-B
24
OX40 Pathway 65
10.91 IFNG IL10 IL2
Sources

GO Terms for Herpes Zoster

About this section

Cellular components related to Herpes Zoster according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.96 HLA-A HLA-B
2 MHC class I protein complex GO:0042612 8.62 HLA-A HLA-B

Biological processes related to Herpes Zoster according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.81 IFNA2 IFNG IL10 IL2
2 interferon-gamma-mediated signaling pathway GO:0060333 9.58 HLA-A HLA-B IFNG
3 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.54 HLA-A HLA-B
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 IFNA2 IFNG IL2
5 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.52 HLA-A HLA-B
6 positive regulation of T cell mediated cytotoxicity GO:0001916 9.49 HLA-A HLA-B
7 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.48 IFNA2 IFNG
8 regulation of regulatory T cell differentiation GO:0045589 9.46 IFNG IL2
9 regulation of immune response GO:0050776 9.46 COL17A1 FCGR3A HLA-A HLA-B
10 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.43 HLA-A HLA-B
11 type I interferon signaling pathway GO:0060337 9.43 HLA-A HLA-B IFNA2
12 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.32 HLA-A HLA-B
13 immune response GO:0006955 9.1 FCGR3A HLA-A HLA-B IFNG IL10 IL2
14 protection from natural killer cell mediated cytotoxicity GO:0042270 8.96 HLA-A HLA-B

Molecular functions related to Herpes Zoster according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IFNA2 IFNG IL10 IL2
Sources

Sources for Herpes Zoster

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....